Articles tagged with Cancer Patients
Researchers found that ITIM-receptor signaling supports AML development and suggests blocking this pathway may be an effective strategy for treatment. The study provides new insights into the immune system's role in cancer and may lead to novel therapies for acute myeloid leukemia.
A phase 1/2 trial of rociletinib in EGFR-mutant non-small cell lung cancer showed a 59% response rate and 13.1 month progression-free survival, offering hope for patients with previously treated disease.
Patients with locally advanced esophageal cancer who survive 5 years after surgery are at risk for recurrence, new primary cancers, and chronic pulmonary disease. Continued surveillance is necessary to mitigate these risks, particularly for patients with nodal metastases.
A Cancer Research UK study found that only a third of bowel cancer patients received physical activity advice, despite evidence showing its link to better survival rates. Most patients who received advice were more likely to be physically active than those who didn't.
A new analysis of the Surveillance, Epidemiology, and End Results (SEER) database found significant variation in health insurance coverage among cancer patients based on demographics and cancer type. Younger, non-White, and rural patients were more likely to be uninsured, while males were less likely than females to have insurance.
Survivors of Hodgkin lymphoma have a persistently increased risk of cardiovascular disease throughout life, with a cumulative risk of 50% at 40 years after diagnosis. The study found that mediastinal radiotherapy and anthracycline-containing chemotherapy significantly increased the risks of cardiovascular events.
New research suggests that persistent swollen lymph glands in the neck are a high-risk indicator for lymphoma. By referring patients with unexplained swollen neck glands for further investigation, doctors can help reduce cancer-related deaths in the UK.
A population-based study found brachytherapy with external beam radiation improved overall survival by 13% for women with inoperable stage 1 endometrial cancer. Brachytherapy was also associated with lower deaths from endometrial cancer after three years.
Researchers discovered that cancer rates among hepatitis C patients are significantly higher than those without the virus. The study found a 2.5 times higher rate of all cancers and almost twice as high when liver cancer is excluded.
A new study by Brigham and Women's Hospital finds that breast conserving therapy was successful in over 90% of women who became eligible after treatment with chemotherapy. Despite this, 31% of those eligible chose mastectomy, highlighting the need for further exploration of patient and surgeon factors.
Researchers identified specific genetic markers in African American women with triple negative breast cancer, associated with improved survival rates. The study suggests that these molecular differences may hold the key to improving treatment outcomes for this high-risk population.
A recent study from Huntsman Cancer Institute found that childhood cancer survivors are more than five times as likely to be enrolled in federal social security disability assistance programs compared to individuals without a cancer history. The study identified survivor socio-demographic and treatment characteristics associated with a...
Researchers have discovered a damaged DNA lesion that may serve as an early biomarker for liver cancer. Polyphenon E, a green tea extract, also shows promise in suppressing the lesion and preventing tumor development.
Researchers have identified methylated DNA markers in blood samples with 80% accuracy, enabling potential non-invasive screening for cancer. The discovery could lead to earlier diagnosis and improved patient outcomes for rare cancers like pancreatic cancer.
The $20 million SU2C-American Cancer Society Lung Cancer Dream Team will focus on targeting KRAS mutant lung cancer using a three-pronged approach. The team aims to develop novel therapies that combine targeted drug therapies with immunotherapies to improve patient outcomes.
A collaborative study by the University of Colorado Cancer Center and National Cancer Institute reports TERT gene promoter alterations in 69% of bladder cancers. The study suggests these alterations may be an early precursor to the disease and could lead to genetic testing for screening.
A large study found that fewer than 10% of patients with adverse pathologic features after surgery received postoperative radiotherapy within six months. Despite strong evidence, the utilization of radiation therapy for these patients is declining in the US.
Multiparametric MRI and ultrasound fusion enables targeted biopsies of high-suspicion foci with increased diagnostic accuracy for prostate cancer. For patients on active surveillance, this method better characterizes the prostate gland and detects higher-grade disease.
Researchers found that long-time consumption of soyfoods boosts immune response against breast tumors, reducing cancer recurrence. Genistein in soyfoods activates anti-tumor immune responses and reduces immunosuppressive mechanisms.
African-American women with ER+ breast cancer experience poorer outcomes due to increased activation of the unfolded protein response (UPR) pathway, reducing sensitivity to tamoxifen treatment. Strategies targeting this pathway could improve therapy effectiveness.
Dr. Mario Capecchi has made significant contributions to cancer research through his development of gene targeting technology, revolutionizing the study of cancer genes and mechanisms of cancer development. He will be presented with the AACR Award for Lifetime Achievement in Cancer Research at the 2015 Annual Meeting.
A research team led by Charles Sawyers and Howard Scher discovered novel antiandrogen enzalutamide, which extended survival among patients with metastatic castration-resistant prostate cancer. The AACR Team Science Award recognizes the team's innovative work in advancing cancer research.
Dr. Carl June is being recognized for his contributions to cancer immunology, particularly his development of chimeric antigen receptor (CAR) T-cell therapy. His work has enhanced the promise of cancer immunotherapy and led to significant breakthroughs in treating leukemia.
David Baltimore is being recognized for his groundbreaking discoveries in immunology, virology, and cancer research. He will present a lecture on microRNAs, leukemia, and hematopoietic stem cells homeostasis at the AACR Annual Meeting 2015.
Margaret Foti, AACR CEO, will receive the Children's Champion Award for her outstanding pediatric cancer advocacy efforts. The award recognizes her leadership in advancing research and treatment for children with cancer.
A recent study by the Journal of the American College of Surgeons found that socioeconomic factors such as income level, education, and hospital type significantly impact lung cancer patients' odds of death within 30 days after surgery. Patients from lower-income households were 25% more likely to die than those in higher-income areas.
A new scoring method called MATH measures genetic variability among cancer cells within tumors from patients with head and neck cancer. High MATH scores correspond to tumors with many differences among gene mutations present in different cancer cells, correlating with lower patient survival.
James Allison, a renowned immunologist, has been recognized for his pioneering discovery that blocking CTLA-4 improves antitumor immune responses. His work led to the development of ipilimumab, an immune checkpoint inhibitor that transformed melanoma treatment.
A study by Dartmouth-Hitchcock's Camilo Fadul and colleagues found no correlation between regulatory T cells (Tregs) and patient survival in glioblastoma. The researchers used a novel epigenetic quantitative analysis methodology to quantify lymphocyte populations, including Tregs, in tumor tissue and peripheral blood.
James P. Allison is being acknowledged for his discovery that blocking CTLA-4 signaling improves antitumor immune responses, leading to the development of ipilimumab, a cancer immunotherapeutic. His research has transformed the lives of patients with melanoma and offers hope for other forms of cancer.
Dr. Coffey will receive the award for his pioneering work on prostate cancer, nuclear matrix, and mentoring of young researchers. He is also recognized for his outstanding leadership skills and advocacy for sustained funding for cancer research.
A new clinical trial found that early initiation of palliative care significantly improved one-year survival rates among patients with late-stage cancer. Additionally, caregivers experienced reduced depression and stress levels when interventions started earlier in the patient's life.
Researchers at Queen's University Belfast have launched a revolutionary personalized treatment program to improve bowel cancer survival rates. The S-CORT Consortium will employ state-of-the-art techniques to define the genetic make-up of bowel cancer cells, collected from over 2,000 patients, and develop personalized care plans.
Recent studies in Cancer Cell and Trends in Immunology review the intricate relationship between the immune system and cancer. Research has shown that harnessing anti-tumor immunity can be a promising approach to treating various cancers.
Researchers James P. Allison and Padmanee Sharma argue that combining targeted therapies with immunotherapy could be key to developing curative treatments for various cancer types, building on promising results from clinical trials.
Women with ductal carcinoma in situ breast cancer underwent axillary lymph node evaluation at high rates, defying guidelines. The study found that 17.7% of women undergoing breast-conserving surgery and 63% of those who had mastectomy underwent axillary evaluation.
A Yale study found that one in five Medicare patients with melanoma experience significant delays in getting surgery, affecting their psychological well-being and healthcare quality. The study analyzed data from over 32,000 Medicare patients and revealed that 22% waited longer than 1.5 months for treatment.
A study by Professor Rama Khokha found that genetically modified mice without TIMP1 and TIMP3 experienced youthful breast tissue, with stem cells remaining functional throughout their lifetime. The results challenge the assumption that large numbers of stem cells increase cancer risk.
Dr. Owen Witte, a pioneer in human leukemias and immune disorders, received the AACR G.H.A. Clowes Memorial Award for his groundbreaking work on tyrosine kinases as drug targets. His discoveries have led to multiple approved targeted therapies, transforming patient outcomes.
A third of breast cancer patients report strong desire for genetic testing but many do not receive relevant discussions with healthcare professionals. This study highlights the unmet need for addressing genetic risk in these patients.
Therapeutic anti-cancer vaccines have been associated with a statistically significant increase in patient survival, but rarely have a noticeable effect on tumor growth. The study suggests that overall survival, rather than progression-free survival, should be the gold standard for evaluating cancer vaccine efficacy.
Breast cancer cells' growth is inhibited by a combination of estradiol and tumor necrosis factor alpha, improving clinical outcomes for some subtypes. The altered gene expression patterns can be used as biomarkers to determine risk and therapy response.
Patients with stage IV cancer prioritize pain management, home deaths, and quality of healthcare over life extension, while caregivers are willing to pay more for these services. The study suggests that patients' preferences should be directly elicited during treatment decision-making.
A clinical trial is enrolling children and adults with graft-versus-host-disease using their own immune cells to target inflammation and reduce organ damage. The personalized cells are derived from the patient's own bone marrow, making them more likely to be effective.
A new review emphasizes the need to decipher immune response dynamics to enhance cancer immunotherapy. Researchers suggest developing combination therapies and biomarker panels to increase treatment impact, as single biomarkers are unlikely to predict patient responses.
A Cancer Research UK review found that older people, women, and less affluent individuals are at a higher risk of emergency cancer diagnoses. The study also revealed that emergency-diagnosed cancers tend to have poorer survival rates compared to those diagnosed through other routes.
A new study found that patients with lower vitamin D levels before treatment for follicular lymphoma have a worse prognosis and are more likely to succumb to the disease or face relapse earlier. Vitamin D deficiency may represent a modifiable risk factor for this type of cancer.
Dr. Lewis C. Cantley is being recognized for his groundbreaking work in discovering the phosphoinositide 3-kinase (PI3K) enzyme and elucidating its role in cancer development. His research has led to the development of personalized cancer therapies targeting the PI3K signaling pathway.
Dr. Lucile Adams-Campbell is recognized for her scientific work in cancer epidemiology and health disparities, as well as her dedication to mentoring minority researchers. She will receive the AACR-MICR Jane Cooke Wright Lectureship at the AACR Annual Meeting 2015.
A lack of disclosure and elevated cancer risk are experienced by the LGBTQI community due to reduced access to healthcare and insurance. Researchers suggest training staff in LGBTQI competencies and collecting gender identity and sexual orientation data to improve patient care.
Dr. Vakoc's work reveals an essential connection between epigenetic regulation and oncogenesis, leading to potential new therapeutic approaches for leukemias and other cancers. He will present his lecture at the AACR Annual Meeting 2015.
The National Cancer Institute has renewed its grant to Norris Cotton Cancer Center, solidifying its status as a Comprehensive Cancer Center. The center offers top-notch patient care, cutting-edge research, and innovative treatments.
Dr. William Hahn receives the 39th annual AACR-Rosenthal Memorial Award for his seminal work on cancer initiation, maintenance, and progression. His research provides a foundation for novel therapeutic approaches now being tested in the clinic.
Low is being recognized for his pioneering development of low molecular weight ligands to deliver attached therapeutic and imaging agents selectively into pathologic cells such as cancer cells. This targeted therapeutic approach improves potency and reduces toxicity.
The Global Cancer Project Map is an online resource connecting the global cancer community, enabling access to cancer projects and expertise. The map covers a range of projects, from prevention to palliative care, and aims to reduce health disparities and strengthen human capital in underserved areas.
A blood test identified patients with advanced colorectal cancer who could benefit from a more intensive chemotherapy regimen, reducing hair loss and other side effects. The study found that patients with higher counts of circulating tumour cells in their blood responded better to treatment.
A new study found that cancer patients have variable knowledge about imaging tests, with most wanting basic education about radiation use and understanding how tests differ. Patients also desired information on potential long-term risks and participation in decision-making about medical imaging.
A breakthrough discovery by Queen's University researcher Madhuri Koti has identified biomarkers that can predict the success of chemotherapy in ovarian cancer patients. This finding holds promise for improving treatment options and increasing patient survival rates.
A new study from Brigham and Women's Hospital found that Asian-Americans diagnosed with cancer have significantly lower cancer-specific mortality rates compared to non-Hispanic white patients. The study analyzed data from over 2.5 million patients and broke down the population into eight subgroups, revealing variations in survival rate...
A new study evaluates currently available screening tools for senior cancer patients taking too many medications. It found that a more comprehensive assessment and monitoring plan is needed to improve treatment outcomes.